hrp0097p1-299 | GH and IGFs | ESPE2023
Polak Michel
, Bouhours-Nouet Natacha
, Tauber Maithé
, van Dommelen Paula
, Khebbeb Sarah
, Castello-Bridoux Claire
, De Buyst Valerie
, Koledova Ekaterina
, Linglart Agnès
Background: The SCOPE French retrospective study follows children affected with growth hormone (GH) disorders treated with recombinant human GH (r-hGH) therapy via the easypod® connected injection device for up to 5 years.Aim: To show the results from an interim analysis of the SCOPE study analysing adherence to r-hGH therapy in a real-world setting and its effect on catch-up growth.Met...